Synthetic Transcriptional Activators for Cancer Immunotherapy
用于癌症免疫治疗的合成转录激活剂
基本信息
- 批准号:10850109
- 负责人:
- 金额:$ 19.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-08 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:Adoptive Cell TransfersAntigensApplications GrantsCRISPR/Cas technologyCell LineCellsCervix carcinomaClinicClinicalDNADNA BindingDevelopmentDisease remissionEngineeringFutureGene ActivationGenesGenetic TranscriptionGoalsHIVHIV-1Hela CellsHuman papillomavirus 18ImmuneImmune systemImmunotherapyIn VitroInvestmentsLengthMalignant NeoplasmsMeasuresMediatingMolecular VaccinesNucleic Acid Regulatory SequencesNucleotidesPatientsPeptidesPopulationPreparationPromoter RegionsPropertyProteinsReporterSafetyT-Cell ActivationT-LymphocyteTechnologyTherapeuticTimeTissuesTranscription CoactivatorTranslationsTumor AntigensTumor EscapeVaccinesWorkanti-tumor immune responsecancer cellcancer immunotherapydesignexperimental studyexpression vectorimmune checkpoint blockadeimmunogenicityin vivoneoplastic cellpromoterprotein expressionresponsetargeted treatmenttherapeutic proteintranscription factor
项目摘要
Cancer immunotherapy is a promising approach to treat cancer by activating a patient’s immune system against
tumor cells and even providing long-term remission. These clinical benefits have led to recent FDA approvals
for immune-checkpoint blockade (ICB), adoptive cell transfer (ACT), and molecular vaccine technologies, and
have also motivated substantial commercial investments for their continued development. Nonetheless, these
therapies are also associated with nonselective immunogenicity—which limits efficacy and harms healthy
tissue. For these treatments to reach their full promise, new strategies are desperately needed to enhance
immunotherapy responses while also minimizing off-target effects. One key challenge with developing
immunotherapies is achieving robust anti-tumor immune responses. Strategies to promote responses include
administering peptide or DNA-encoded T-cell antigens, designed to expand T-cell populations against tumor
cells. These vaccines have demonstrated a potential to activate T cells, but often provide limited efficacy due to
immune evasion by tumor cells. Recently, engineered transcription factor (ETF) proteins were shown to induce
protein expression of latent HIV-infected cell reservoirs by targeting the HIV-1 promoter. Inspired by this
approach, we envisioned developing new ETF proteins that induce expression of tumor antigens and, in turn,
facilitate immune recognition of cancer cells. Although CRISPR technologies are also used for gene activation,
therapeutic applications remain limited due to insufficient safety and intracellular delivery properties.
Our overarching goal in this proposal is to demonstrate using an ETF to induce expression of tumor antigens
in vitro. Over time, we will establish the efficacy of ETFs, which will guide designs of future in vivo experiments
(not included in this proposal) and future grant applications. We will begin these studies by developing ETF
activators that induce expression of antigenic proteins associated with human papilloma virus (HPV)-18, which
is associated with cervical carcinoma. We selected HPV-18 because it is an ideal starting point for developing
ETFs in our group for several reasons. One reason is that the Upstream Regulatory Region (URR) and reporter
cell line (HeLa) are well-characterized. Another reason is that these studies build upon the prior work with HIV. If
successful, we plan to develop additional ETF proteins as a facile approach for enhancing tumor cell
immunogenicity in the clinic. We will develop ETFs through the design, preparation, and characterization of ZF
building blocks, which we will assemble to recognize promoter region genes that are 18 nucleotides in length.
We will also incorporate a ‘transcriptional activator’ to induce protein transcription and translation. We will
evaluate ETF-mediated activation by encoding these constructs into a mammalian expression vector, followed
by measuring expression of the protein antigen in cancer cells. We will also prepare synthetic ETFs as
therapeutic proteins to enable DNA-binding studies and to enhance intracellular delivery properties.
癌症免疫疗法是一种通过激活患者的免疫系统来治疗癌症的有希望的方法,
肿瘤细胞,甚至提供长期缓解。这些临床益处导致最近FDA批准
用于免疫检查点阻断(ICB)、过继细胞转移(ACT)和分子疫苗技术,以及
也推动了大量的商业投资,以促进其持续发展。但这些
治疗还与非选择性免疫原性有关,这限制了疗效并损害了健康。
组织.为了使这些治疗方法充分发挥作用,迫切需要新的策略来加强
免疫治疗反应,同时也最大限度地减少脱靶效应。发展中国家面临的一个关键挑战
免疫疗法正在实现强大的抗肿瘤免疫应答。促进对策的战略包括
施用肽或DNA编码的T细胞抗原,设计用于扩增T细胞群以对抗肿瘤
细胞这些疫苗已经证明了激活T细胞的潜力,但由于免疫缺陷,通常提供有限的功效。
肿瘤细胞的免疫逃避。最近,工程化的转录因子(ETF)蛋白被显示诱导
通过靶向HIV-1启动子,使潜伏的HIV感染细胞库的蛋白质表达。受此启发
方法,我们设想开发新的ETF蛋白,诱导肿瘤抗原的表达,反过来,
促进癌细胞的免疫识别。尽管CRISPR技术也用于基因激活,
由于安全性和细胞内递送性质不足,治疗应用仍然受到限制。
我们在这项提案中的首要目标是证明使用ETF诱导肿瘤抗原的表达
体外随着时间的推移,我们将确定ETF的功效,这将指导未来体内实验的设计
(not包括在本提案中)和未来的赠款申请。我们将开始这些研究,
诱导与人乳头瘤病毒(HPV)-18相关的抗原蛋白表达的激活剂,
与宫颈癌有关。我们选择HPV-18是因为它是开发HPV-18的理想起点。
ETF在我们组中有几个原因。一个原因是上游监管区(URR)和报告人
细胞系(HeLa)被充分表征。另一个原因是,这些研究建立在以前对艾滋病毒的研究基础上。如果
成功后,我们计划开发另外ETF蛋白作为增强肿瘤细胞
临床上的免疫原性。我们将通过ZF的设计、制备和表征来开发ETF
构建模块,我们将组装这些模块来识别长度为18个核苷酸的启动子区基因。
我们还将引入一个“转录激活因子”来诱导蛋白质的转录和翻译。我们将
通过将这些构建体编码到哺乳动物表达载体中来评估ETF介导的活化,
通过测量癌细胞中蛋白质抗原的表达。我们还将准备合成ETF,
治疗性蛋白质以使DNA结合研究成为可能并增强细胞内递送性质。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IGOR B RONINSON其他文献
IGOR B RONINSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IGOR B RONINSON', 18)}}的其他基金
Synthetic Transcriptional Activators for Cancer Immunotherapy
用于癌症免疫治疗的合成转录激活剂
- 批准号:
10868915 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
METABOLIC ANALYSIS INSTRUMENTATION TO ENHANCE TARGETED THERAPEUTICS STUDIES
代谢分析仪器可增强靶向治疗研究
- 批准号:
10400414 - 财政年份:2014
- 资助金额:
$ 19.92万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 19.92万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 19.92万 - 项目类别: